Skip to content

KPHMW: 1 Funds Holding, Catalyst in 47d | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Free TrialStart 14-Day Free Trial

Home›Companies›KIORA PHARMACEUTICALS INC (KPHMW)

KIORA PHARMACEUTICALS INC

KPHMW

Held by 1 specialist biotech fund

1 fund opened new positions. Next phase2 readout (KIO-104): Nov 2026.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

3.0/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

Phase2 readout in 47 days●●

Held by 1 specialist fund●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

1 specialist fund hold KPHMW with a Phase 2 in 47 days for KIO-104 (Macular Edema)

+1 more upcoming catalyst

Perceptive Advisors

Fund Holdings

Perceptive AdvisorsNew

AI Signal

Signal Note: Perceptive Advisors Initiates KIORA (KPHMW)

Perceptive Advisors (Edelman's clinical-stage focused fund) opened a $1.2M position in KIORA, a pre-revenue ophthalmology biotech with two near-term phase 2 readouts: KIO-104 for macular edema (Nov 2026) and KIO-301 (100 μg) for retinitis pigmentosa (Aug 2027). The timing and fund pedigree suggest conviction in the pipeline quality, though initiation size and lack of visible co-investor concentration limit this to a moderate signal pending additional institutional validation.

Unlock full AI analysis — 14-day free trial

Catalysts

Phase 2Q4 2026KIO-104Macular EdemaNCT06825702

Primary: Safety and Tolerability (23months)Enrollment:Target 28Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2Q3 2027100 μg KIO-301Retinitis PigmentosaNCT06628947

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GPerceptive Advisors10.0%Aug 10, 2026

SC 13GPerceptive Advisors10.0%Apr 13, 2026

Position Details

Perceptive AdvisorsNEW POSITIONAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

NTRA1 fund ASND1 fund IRD1 fund SLDB1 fund SYRE1 fund TNGX1 fund NBIX1 fund NUVL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: